Details for New Drug Application (NDA): 074368
✉ Email this page to a colleague
NDA 074368 describes NADOLOL, which is a drug marketed by Alembic, Amneal Pharms Co, Aurobindo Pharma, Beximco Pharms Usa, Chartwell Rx, Heritage Pharma, Invagen Pharms, Novast Labs, Rising, Rk Pharma, Sandoz, Teva Pharms, Zydus Pharms, Impax Labs, and Natco Pharma, and is included in sixteen NDAs. It is available from sixteen suppliers. Additional details are available on the NADOLOL profile page.
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for 074368
| Tradename: | NADOLOL |
| Applicant: | Teva Pharms |
| Ingredient: | nadolol |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 074368
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
| Approval Date: | Aug 31, 1994 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 120MG | ||||
| Approval Date: | Aug 31, 1994 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 160MG | ||||
| Approval Date: | Aug 31, 1994 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
